Subhangi Das, Bankura Sammilani College
OXGENE has developed scalable gene therapy technology, marking the day as the launch of its scalable, plasmid-free technical system for AAV. OXGENE ‘s new TESSA technology is a great illustration of the change in AAV manufacturing.
Adeno associated virus or AAV having benefits such as low immunogenicity and a favorable safety profile is used to deliver gene therapies to a patient.
Manufacturing systems have not kept up with advances in technology, leaving these therapies subject to inherent batch-to-batch variability, costly, and difficult to produce at scale.
This new technology is expected to transform the way AAV is manufactured. OXGENE has many developing features that validated TESSA vectors for AAV2,5,6 and 9 to suffice demands for industrial works, large projects.
This invention may be a boon to the biotechnological field, removing the reliance on expensive and limiting plasmids for AAV manufacture.
Source: https://www.oxgene.com/
Visit https://bioxone.in// for more updates.
DNA Methylation Role in Ageing Human Muscles
-Thota Kanishka Rao, Amity University Kolkata Skeletal muscle is one of the three major muscle types, composed of skeletal muscle tissue which is under the voluntary control of the somatic system. Maintaining muscle mass and performance into older age is prime for human health-span and quality of life. Five to ten per cent of older […]